Other Neurological Disorders Publications International

1. Bachoud-Lévi AC; on behalf the Multicentric Intracerebral Grafting in Huntington's Disease Group. Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial. Mov Disord. 2020 Aug;35(8):1323-1335. doi: 10.1002/mds.28201. Epub 2020 Jul 15. PmiD: 32666599.
2. Polgar S, Buultjens M, Wijeratne T, Finkelstein DI, Mohamed S, Karimi L. The Placebo Response in Double-Blind Randomised Trials Evaluating Regenerative Therapies for Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis. 2022;12(3):759-771. doi: 10.3233/JPD-212610. PmiD: 35034910.
3. Paton MCB, Wall DA, Elwood N, Chiang KY, Cowie G, Novak I, Finch-Edmondson M. Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies. Cytotherapy. 2022 Jan;24(1):2-9. doi: 10.1016/j.jcyt.2021.07.001. Epub 2021 Aug 10. PmiD: 34384698.
4. Wang J, Tian Y, Shi X, Feng Z, Jiang L, Hao Y. Safety and Efficacy of Cell Transplantation on Improving Motor Symptoms in Patients With Parkinson's Disease: A Meta-Analysis. Front Hum Neurosci. 2022 May 6;16:849069. doi: 10.3389/fnhum.2022.849069. PmiD: 35601911; PMCID: PMC9120834.
5. Miao X, Wu X, Shi W. Umbilical cord mesenchymal stem cells in neurological disorders: a clinical study.
6. Mohseni R, Hamidieh AA, Shoae-Hassani A, Ghahvechi-Akbari M, Majma A, Mohammadi M, Nikougoftar M, Shervin-Badv R, Ai J, Montazerlotfelahi H, Ashrafi MR. An open-label phase 1 clinical trial of the allogeneic side population adipose-derived mesenchymal stem cells in SMA type 1 patients. Neurol Sci. 2022 Jan;43(1):399-410. doi: 10.1007/s10072-021-05291-2. Epub 2021 May 25. PmiD: 34032944.
7. Carstens M, Haq I, Martinez-Cerrato J, Dos-Anjos S, Bertram K, Correa D. Sustained clinical improvement of Parkinson's disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells. J Clin Neurosci. 2020 Nov;81:47-51. doi: 10.1016/j.jocn.2020.09.001. Epub 2020 Sep 25. PmiD: 33222965.
8. Li H, Yuan F, Du Y, Pan T, Wen W, Li S, Wang L, Lu A. Umbilical cord blood stem cells transplantation in a patient with severe progressive supranuclear palsy: a case report. Journal of Medical Case Reports. 2021 Nov 29;15(1).
9. Moon H, Kim B, Kwon I, Oh Y. Challenges involved in cell therapy for Parkinson’s disease using human pluripotent stem cells. Front Cell Dev Biol. 2023;11.
10. Izrael M, Chebath J, Molakandov K, Revel M. Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases. Adv Drug Deliv Rev. 2025;115525.
11. Ren H, Wang Y, Chen Y, Ma F, Shi Q, Wang Z, Gui Y, Liu J, Tang H. The therapeutic effects of induced pluripotent stem cell‐derived mesenchymal stem cells on Parkinson’s disease. IUBMB Life. 2024;77(1).
12. Chang M, Lee S. Human Pluripotent Stem Cell-Based Therapies for Parkinson’s Disease: Challenges and Potential solutions. Yonsei Med J. 2025;66(7):395.
13. Morizane A, Yamasaki E, Shindo T, Anazawa T, Sawamoto N, Shima A, Yamakado H, Nakanishi E, Sawamura M, Taruno Y, Doi D, Kikuchi T, Kawasaki Y, Saito MK, Kikuchi T, Arakawa Y, Miyamoto S, Nakamoto Y, Takahashi R, Takahashi J. Control of immune response in an iPSC-based allogeneic cell therapy clinical trial for Parkinson’s disease. Cell Stem Cell. 2025.
14. Yang L, Liu S, Liu Y, Zhu F, Xiong M, Hu D, Zhang W. Therapeutic role of neural stem cells in neurological diseases. Front Bioeng Biotechnol. 2024;12.
15. Mattei V, Monache SD. Mesenchymal stem cells and their role in neurodegenerative diseases. Cells. 2024;13(9):779.